Novel Live Attenuated Type 1 Poliomyelitis Vaccines (PATH)
- Generic Name
- Novel Live Attenuated Type 1 Poliomyelitis Vaccines (PATH)
Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
Phase 2
Not yet recruiting
- Conditions
- Poliomyelitis
- Interventions
- Biological: Novel Oral Polio Vaccine Type 2 (nOPV2)Biological: Placebo (Sterile Water)
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- PATH
- Target Recruit Count
- 675
- Registration Number
- NCT06895486
- Locations
- 🇵🇦
Cevaxin - 24 de Diciembre, Panama, Panama
🇵🇦Cevaxin - Ave. México, Panama, Panama
🇵🇦Cevaxin - Chorrera, Panama, Panama
Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
Phase 1
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)Biological: Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- PATH
- Target Recruit Count
- 205
- Registration Number
- NCT04529538
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Pharmaron CPC, Inc., Baltimore, Maryland, United States
🇺🇸University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath